Integrated Development Advantage Quotient Sciences offers an end-to-end drug development and manufacturing accelerator that breaks down silos and accelerates timelines, making it attractive to biopharma needing faster go-to-market. Position as a sole partner to streamline programs from discovery to clinic and manufacturing, reducing management overhead and cycle times.

Global Manufacturing Power With facilities in the US and UK and a scalable platform, Quotient can support global supply, regulatory readiness, and rapid scale-up for diverse modalities, including rare diseases and biologics. Position as a single partner to simplify cross-border supply and regulatory alignment for international trials.

Proven Partnership Track A growing portfolio of strategic collaborations with Ipsen, Iris ENG, Lindus Health and CPI demonstrates adaptability across early clinical to late-stage development and manufacturing; the awards recognition reinforces credibility. Approach targets with co-development and milestone-based engagements, enabling cross-sell across development and manufacturing services.

Translational Pharmaceutics The Translational Pharmaceutics platform enables rapid iteration from concept to clinic, helping clients accelerate timelines while controlling costs, with potential across RNA-based therapies and other modalities through partnerships. Target biotech and larger pharma seeking speed-to-patient and flexible CMC strategies.

Rare Disease Leadership Quotient’s track in rare and ultra-rare disease programs, including collaborations for FOP and RNA-focused work, plus patient recruitment partnerships, positions it as a strategic partner for programs requiring specialized development and streamlined access to trials. Target rare disease developers needing integrated development and trial execution.